The Effects of Somatostatin Analogue on Ovarian Response to Ovulation Induction in Patients with Polycystic Ovarian Syndrome.
- Author:
Hyung Sik CHU
;
Hee Dong CHAE
;
Chung Hoon KIM
;
Byung Moon KANG
;
Yoon Seok CHANG
;
Eun Hee KANG
- Publication Type:Original Article ; Randomized Controlled Trial
- Keywords:
Somatostatin analogue;
Polycystic ovarian syndrome;
Ovulation induction;
Growth hormone;
Insulin-like growth factor 1
- MeSH:
Abortion, Spontaneous;
Chorionic Gonadotropin;
Clomiphene;
Estradiol;
Female;
Gonadotropins;
Growth Hormone;
Humans;
Incidence;
Infertility;
Insulin-Like Growth Factor I;
Menstrual Cycle;
Octreotide;
Ovarian Hyperstimulation Syndrome;
Ovulation Induction*;
Ovulation*;
Polycystic Ovary Syndrome*;
Pregnancy;
Pregnancy Rate;
Pregnancy, Multiple;
Somatostatin*
- From:Korean Journal of Obstetrics and Gynecology
1999;42(3):496-503
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: To determine whether the somatostatin analogue, octreotide, given concunently with human menopausal gonadotropin (HMG) affects ovarian response, ovulation induction outcome, and serum levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) in infertile patients with polycystic ovarian syndrome (PCOS) resistant to clomiphene citrate (CC). METHODS: From August 1996 to June 1998, 42 infertile patients with PCOS urresponsive to CC were enrolled in the present study. Women who had other infertility factors were excluded from this study. Patients were randomly allocated either to combined HMG and octreotide treatment (treatment group) (n=21) or HMG alone (control group) (n=21). In the treatment group, 100 micrograms of octreotide were administered daily concomitantly with HMG from the 3rd day of menstrual cycle to the preceding day of human chorionic gonadotropin (HCG) injection. RESULTS: Patient's characteristics were comparable in both groups. One cycle in the control group was abandoned because of excessive follicular development. However, none of the cycles in the treatment group was abandoned. There were no differences in the number of HMG ampules required and the duration of HMG administration between the two groups. The number of follicles > 14mm diameter on the day of HCG injection was significantly less in the treatment group than that in the control group (p<0.01). The serum estradiol level on the day of HCG injection was also significantly lower in the treatment group, with 1391.0 +/- 695.5 pg/ml compared with 2217.5 +/- 811.6pg/ml in the control group (p<0.001). The incidence of severe ovarian hyperstimulation syndrome seemed to be lower in the treatment group, but the difference did not achieve significance (4.9% vs 23.8%). There were no differences in the clinical pregnancy rate, miscarriage rate and multiple pregnancy rate between the two groups. Although serum GH levels were comparable between the two groups, serum IGF-1 level on the day of HCG injection was significantly higher in the treatment gmup than that in the control group (p<0.001). CONCLUSION: This study suggests that the combined octreotide and HMG treatment could improve hormonal milieu and folliculogenesis compared to HMG alone, and therefore may be effective in ovulation induction for patients with PCOS resistant to CC.
